Eastwood Bio-Medical Canada Inc. (TSXV:EBM) have seen a year over year change of sales growth of -0.14519.  The 311750 market value company based out of Canada is an important player in the Other sector.

While sales growth can be a key driver for a company’s stock performance, there are many other factors to consider as well.  Here we’ll take a look at several other notable indicators.

Aurora Cannabis(NYSE:ACB) and KushCo Holdings(NASDAQOTH:KSHB) are two marijuana stocks that are about as different as night and day. Aurora claims a market cap of more than $5.7 billion and produces cannabis for the Canadian recreational and medical marijuana markets and international medical marijuana markets. KushCo’s market cap is less than $460 million. The company provides packaging solutions primarily for the U.S. cannabis industry.

“Hey, look at the stock!” It was a Thursday in late September in the Colorado offices of Leafbuyer technologies, a small tech company focused on cannabis. Like most startups, it’s a little obsessed with its stock price, which it has a staffer assigned to monitor. This day, it was going wild.

Usually, Leafbuyer’s stock would do about 200,000 to 300,000 trades in a day. This day, there had been three million by noon. By close, it done $10 million worth of trades, ending up by more than 60 percent.

Last week Quintessential Capital Management and Hindenburg Researched released a short-seller report on Aphria Inc. (TSX:APHA) that sent the stock tumbling 34% between December 3 – 5.

Eve & Co Incorporated (TSX-V: EVE; OTCQB: EEVVF) (“Eve & Co” or the “Company”) is pleased to announce that as of December 7, 2018, Health Canada authorized Natural MedCo Ltd., a wholly-owned subsidiary of the Company, to use its previously constructed 100,000 sq. ft. second flowering room as a grow area, and a packaging room as an operations area. 

With the addition of these approved areas, Eve & Co now has 220,000 sq. ft. of licenced grow and operation areas. The Company expects harvesting to commence at its newly licenced second flowering room by late March 2019.

At seemingly every turn this year, the marijuana industry has made history. In Canada, nine decades of recreational marijuana prohibition was tossed aside in favor of legalization via the Cannabis Act. This should, once the industry is fully up to speed, generate billions of dollars in added annual sales for the industry.

In the United States, two more states approved medical cannabis (Utah and Missouri), bringing the total number of states with legalized medical weed to 32. Meanwhile, Vermont and Michigan gave the green light to adult-use pot, upping the number of recreationally legal states to 10.

Aurora strikes Mexico deal with Farmacias Magistrales

As I've been predicting since I first started covering the field in late 2016, Big Tobacco is diving headfirst into legal cannabis.

Altria Group Inc. (NYSE: MO), maker of Marlboro cigarettes and other major brands, said early last Friday, Dec. 7, that it's taking a $1.8 billion, 45% equity stake in Canadian cannabis leader Cronos Group Inc. (Nasdaq: CRON). Plus, Altria has the option to take over Cronos through 55% ownership over the next four years.

Constellation Brands's relatively healthy revenue growth in the U.S. beer market, paired with strong profitability and a new investment in cannabis makes the stock one of Cowen's top stock picks heading into 2019.

Marijuana stocks are hogging the spotlight, with many investors asking if they should invest in marijuana stocks…and how to invest in marijuana stocks. And for good reason. Canada legalized the adult use of recreational pot on October 17, the first industrialized country to do so. Countries like Germany, Australia, and Italy are heading in the same direction.

Here in the U.S., recreational marijuana use is legal in 10 states and Washington, D.C. Medical marijuana use is legal in 33 states. And those numbers are growing.

Recreational marijuana use in the U.S. is still illegal on the federal level, but states that have legalized it are rolling in money. The U.S. marijuana market is projected to hit $22.0 billion by 2022.